MyHealthTest (MHT) is a new direct-to-consumer pathology test service using online ordering of test kits, home based dried blood spot (DBS) sample collection, postal delivery of samples to the MHT laboratory for analysis and a secure on-line portal to deliver test results directly to consumers and their doctors. MHT offers convenience, cost savings and empowerment to consumers, promoting improved engagement with their doctor through deeper awareness and direct involvement in monitoring and managing their own health, improving health and wellness. MHT owns and manages the entire chain of service, from online store to laboratory and online results portal.

Busy lifestyles and the inconvenience of doctor and pathology lab visits are key factors in the low compliance to routine monitoring of chronic diseases. The improved convenience of ordering and taking tests, and accessing results at home combined with the reassurance of accurate testing will improve health outcomes, especially for ru...
MyHealthTest (MHT) is a new direct-to-consumer pathology test service using online ordering of test kits, home based dried blood spot (DBS) sample collection, postal delivery of samples to the MHT laboratory for analysis and a secure on-line portal to deliver test results directly to consumers and their doctors. MHT offers convenience, cost savings and empowerment to consumers, promoting improved engagement with their doctor through deeper awareness and direct involvement in monitoring and managing their own health, improving health and wellness. MHT owns and manages the entire chain of service, from online store to laboratory and online results portal.

Busy lifestyles and the inconvenience of doctor and pathology lab visits are key factors in the low compliance to routine monitoring of chronic diseases. The improved convenience of ordering and taking tests, and accessing results at home combined with the reassurance of accurate testing will improve health outcomes, especially for rural / remote individuals and the time-poor.

MHT’s first commercial offering is a test for HbA1c, a test for the long-term management of diabetes. The NH&MRC and Diabetes Australia recommend testing is performed at least once every 6 months, ideally every 3 months. Maintaining HbA1c levels within the recommended range has been proven to delay or reduce the onset of illnesses associated with diabetes such as kidney disease, stroke, heart disease and blindness. There are approximately 1.1 million Australians currently living with diabetes, however there are only approx 1.2M HbA1c test performed annually. The greater convenience and accessibility of testing via MHT will improve testing compliance and aid in the reduction of diabetes associated illnesses.

HbA1c has recently been granted reimbursement for diagnosis of diabetes (Nov 2014) and can also be used to diagnose pre-diabetes. It is estimated that in addition to the 1.1M people living with diabetes there are an additional 600,000 people with undiagnosed diabetes and that more than 16% of adults aged 25 and over have pre-diabetes in Australia. MHT’s test will make annual screening for those at risk easy and accessible.

The test has been proven to be equivalent to conventional blood testing, results from a study performed at the ANU have been published in a scientific peer-reviewed journal - BMC Clinical Pathology.

Further tests are under development including tests for prostatic and thyroid disease.
More information

Employees

Marianne Gould
Admin
Marianne Gould

Recommendations

Anne-Marie Perret Advisor at CycleLifeHQ

My HealthTest is doing some very exciting work in the area of dried blood spot testing. Their work will make it easier for people with chronic diseases such as diabetes to monitor their condition. With health costs rising making it easier for people to test for a disease or the likelihood of a disease should ease the burden on the health care system of supporting chronic diseases.

The team behind MHT have a wealth of experience that they are bringing to bear on this problem area for our health system and sufferers or potential sufferers of chronic disease. The team has has a great vision for MHT and excellent skills to execute on this idea. The work completed to date on the HbA1c test has proved to be very successful and I have no doubt they will have the same success with other tests over time.

Murray Rankin

MHT recently won a large grant under the Commonwealth Gov’t Entrepreneur Program. MHT was rated as highly meritorious and was seen as a disruptive force as a medical innovation, simultaneously targeting social inclusion, improved medical access for the aged, disabled, chronic disease suffers and longer term those in rural, remote and indigenous communities. MHT's core value proposition included convenience, greater patient satisfaction and sample collection comfort, improved health monitoring, reduced health system costs, enhanced support for the target community segments and non-refrigerated transport advantages. The international management and advisory team have deep health innovation experience and some are global authorities in chronic disease public policy and research. Success is likely to contribute to significant national health system cost reductions and overall healthcare savings. I recommend MHT.

Murray Rankin
Commercialisation Adviser
Accelerating Commercialisation

Marcus Dawe

The simplicity and ease of ordering diagnostics from MyHealthTest makes it compelling for anyone who needs to get health tests done and be able to access the results when they want with whichever clinician they need to share with.

This is a revolution for health consumers in saving time and money whilst still maintaining quality and confidence in diagnostics. Looking forward to more tests coming online so we can all benefit as consumers. This is very disruptive for the current high cost inefficient patient-doctor-pathology lab-doctor-patient pathway...

The first mover advantage of MyHealthTest makes it a global business with many countries markets ready for disruption. Focussing on chronic disease tests as the first products means they are focussed immediately on taking costs out of the health system and profiting from innovation that has public good.